Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Musaberk Goksel

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Polycythemia vera with uncommon presentationsAyse P Dincer, Seshan Subramanian, Musaberk Goksel
The Lancet. Oncology|June 18, 2021
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 studyChung-Han Lee, Amishi Yogesh Shah, Drew Rasco, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Polycythemia vera with uncommon presentationsAyse P Dincer, Seshan Subramanian, Musaberk Goksel
The Lancet. Oncology|June 18, 2021
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 studyChung-Han Lee, Amishi Yogesh Shah, Drew Rasco, et al.
Pageof 1